136 related articles for article (PubMed ID: 12478016)
1. High incidence of central nervous system involvement in patients with breast cancer treated with epirubicin and docetaxel.
Abali H; Celik I
Am J Clin Oncol; 2002 Dec; 25(6):632-3. PubMed ID: 12478016
[No Abstract] [Full Text] [Related]
2. [A case of recurrent breast cancer successfully treated with docetaxel].
Koshizuka K; Hada M; Muto S; Hagiwara J; Nakagomi H; Takano K; Kamiya K; Tada Y
Gan To Kagaku Ryoho; 1999 Sep; 26(10):1479-81. PubMed ID: 10500538
[TBL] [Abstract][Full Text] [Related]
3. Atrial fibrillation during adjuvant chemotherapy with docetaxel: a case report.
Palma M; Mancuso A; Grifalchi F; Lugini A; Pizzardi N; Cortesi E
Tumori; 2002; 88(6):527-9. PubMed ID: 12597151
[TBL] [Abstract][Full Text] [Related]
4. Taxoids in combination with epirubicin: the search for improved outcomes in breast cancer.
Pagani O
Semin Oncol; 1998 Oct; 25(5 Suppl 12):23-6. PubMed ID: 9865708
[TBL] [Abstract][Full Text] [Related]
5. [A case of advanced recurrent breast cancer responding to treatment with weekly docetaxel combined with doxorubicin].
Sawada M; Ono Y; Fukushima M
Gan To Kagaku Ryoho; 2003 Feb; 30(2):259-62. PubMed ID: 12610876
[TBL] [Abstract][Full Text] [Related]
6. Combined analysis of two phase II trials in patients with primary and advanced breast cancer with epidoxorubicin and docetaxel+granulocyte colony stimulating factor.
Wenzel C; Locker GJ; Schmidinger M; Rudas M; Taucher S; Gnant MF; Jakesz R; Steger GG
Anticancer Drugs; 2002 Jan; 13(1):67-74. PubMed ID: 11914643
[TBL] [Abstract][Full Text] [Related]
7. High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel.
Crivellari D; Pagani O; Veronesi A; Lombardi D; Nolè F; Thürlimann B; Hess D; Borner M; Bauer J; Martinelli G; Graffeo R; Sessa C; Goldhirsch A;
Ann Oncol; 2001 Mar; 12(3):353-6. PubMed ID: 11332148
[TBL] [Abstract][Full Text] [Related]
8. Docetaxel and epirubicin plus G-CSF mobilize hematopoietic progenitors in breast cancer.
Pierelli L; Leone G; Cortesi E; Martelli O; Perillo A; Mancuso S; Scambia G
Ann Oncol; 1999 Dec; 10(12):1531-2. PubMed ID: 10643552
[No Abstract] [Full Text] [Related]
9. [A case of breast cancer with multiple metastases effectively treated with long-term administration of docetaxel, aclarubicin and UFT].
Ishihama H
Gan To Kagaku Ryoho; 2001 Nov; 28(12):1901-4. PubMed ID: 11729484
[TBL] [Abstract][Full Text] [Related]
10. Docetaxel and epirubicin in advanced breast cancer.
Sessa C; Pagani O
Oncologist; 2001; 6 Suppl 3():13-6. PubMed ID: 11346679
[TBL] [Abstract][Full Text] [Related]
11. Capecitabine in combination with docetaxel and epirubicin in patients with previously untreated, advanced breast carcinoma.
Venturini M; Durando A; Garrone O; Colozza MA; Contu A; Stevani I; Genta F; Bighin C; Lambiase A; Del Mastro L
Cancer; 2003 Mar; 97(5):1174-80. PubMed ID: 12599222
[TBL] [Abstract][Full Text] [Related]
12. High-dose epirubicin plus docetaxel at standard dose with lenograstim support as first-line therapy in advanced breast cancer.
Milla-Santos A; Milla L; Rallo L; Solano V
Am J Clin Oncol; 2001 Apr; 24(2):138-42. PubMed ID: 11319287
[TBL] [Abstract][Full Text] [Related]
13. Immediate effects of docetaxel alone or in combination with epirubicin on cardiac function in advanced breast cancer.
Syvanen K; Ekholm E; Anttila K; Salminen E
Anticancer Res; 2003; 23(2C):1869-73. PubMed ID: 12820471
[TBL] [Abstract][Full Text] [Related]
14. Docetaxel in combination with epirubicin in metastatic breast cancer: pharmacokinetic interactions.
Ceruti M; Tagini V; Recalenda V; Arpicco S; Cattel L; Airoldi M; Bumma C
Farmaco; 1999; 54(11-12):733-9. PubMed ID: 10668172
[TBL] [Abstract][Full Text] [Related]
15. [A case of inflammatory breast cancer achieving pathological complete response by primary systemic therapy with CEF (cyclophosphamide, epirubicin, 5-fluorouracil) followed by docetaxel].
Sagara Y; Rai Y; Sagara Y; Tamada S; Tsuchimochi S; Takahama T; Matsuyama Y; Ando M; Ooi Y; Sagara Y
Gan To Kagaku Ryoho; 2007 Jan; 34(1):77-80. PubMed ID: 17220675
[TBL] [Abstract][Full Text] [Related]
16. Two special types of breast cancer presenting as progressive disease after neoadjuvant chemotherapy with docetaxel plus doxorubicin.
Takahashi T; Akashi-Tanaka S; Fukutomi T; Watanabe T; Katsumata N; Miyakawa K; Hasegawa T; Tsuda H
Breast Cancer; 2001; 8(3):234-7. PubMed ID: 11668246
[TBL] [Abstract][Full Text] [Related]
17. [A patient with advanced breast cancer refractory to chemotherapy accompanied by carcinomatous pleurisy and multiple bone metastasis that responded to combination therapy with high-dose toremifene and docetaxel].
Suzuki M
Gan To Kagaku Ryoho; 2007 Jan; 34(1):69-72. PubMed ID: 17220673
[TBL] [Abstract][Full Text] [Related]
18. Breast tumour growth inhibition in vitro through the combination of cyclophosphamide/metotrexate/5-fluorouracil, epirubicin/cyclophosphamide, epirubicin/paclitaxel, and epirubicin/docetaxel with the bisphosphonates ibandronate and zoledronic acid.
Vogt U; Bielawski KP; Bosse U; Schlotter CM
Oncol Rep; 2004 Nov; 12(5):1109-14. PubMed ID: 15492801
[TBL] [Abstract][Full Text] [Related]
19. [Docetaxel (Taxotere) in combination with anthracycline, capecitabin (Xeloda) and new drugs].
Galligioni E
Tumori; 2001; 87(1 Suppl 2):S1-9. PubMed ID: 11357871
[No Abstract] [Full Text] [Related]
20. Docetaxel plus epidoxorubicin as neoadjuvant treatment in patients with large operable or locally advanced carcinoma of the breast: a single-center, phase II study.
de Matteis A; Nuzzo F; D'Aiuto G; Labonia V; Landi G; Rossi E; Mastro AA; Botti G; De Maio E; Perrone F
Cancer; 2002 Feb; 94(4):895-901. PubMed ID: 11920456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
